Nicox Gains China NDA Filing for NCX 470 Glaucoma Drug via Ocumension Partnership

A single Phase 3 clinical data package now underpins regulatory submissions in two major markets: Nicox SA has confirmed that its exclusive China licensee, Ocumension Therapeutics, filed an NDA for NCX 470 with the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) on 10 August 2026, using the same dossier submitted to the U.S. FDA earlier this year.

The shared data package spans the Mont Blanc and Denali Phase 3 trials, the latter of which was designed with Chinese clinical sites specifically to satisfy NMPA clinical requirements for open-angle glaucoma and ocular hypertension. For regulatory affairs teams managing multi-jurisdictional dossiers, the structure is instructive: embedding territory-specific sites within a single global trial program allowed Nicox and Ocumension to compress the China filing timeline materially after the U.S. submission closed.

Ocumension brings an established ophthalmology commercial infrastructure in China, including an existing sales force already marketing Nicox's ZERVIATE. That operational readiness reduces the gap between a potential NMPA approval and commercial launch, a variable that QA and supply-chain leads will need to factor into technology transfer and batch release planning. Ocumension has paid Nicox €18 million in license fees for China development and commercialisation rights across multiple agreements dating to 2018.

The regulatory pipeline extends beyond China and the United States. Phase 3 trials to support a Japan submission have been running since summer 2025, positioning NCX 470 across three major regulated markets within a compressed window. Nicox's CEO Gavin Spencer cited a 12-to-24-month horizon for multiple approvals and launches, a timeline that will stress-test both partners' process validation readiness and post-approval change management protocols under their respective regional frameworks.

The NMPA review clock for NCX 470 now runs in parallel with the FDA review, making the next 12 to 18 months a critical period for monitoring dual-jurisdiction inspection readiness and any bridging data requests that could affect dossier alignment.

Source: Nicox SA via GlobeNewswire, 10 August 2026.